Osseor
strontium ranelate
Strontium ranelate
Keep this leaflet. You may need to read it again.
If you have any further questions, ask your doctor or your pharmacist.
This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.
What OSSEOR is and what it is used for
What you need to know before you take OSSEOR
How to take OSSEOR
Possible side effects
How to store OSSEOR
Contents of the pack and other information
Medicinal product no longer authorised
OSSEOR is a medicine used to treat severe osteoporosis:
in postmenopausal women,
in adult men,
at high risk of fracture, for whom other alternative treatments are not possible. In postmenopausal women, strontium ranelate reduces the risk of fracture at the spine and at the hip.
Aboutosteoporosis
Your body is constantly breaking down old bone and making new bone tissue. If you have osteoporosis, your body breaks down more bone than it forms so that gradually bone loss occurs and your bones become thinner and fragile. This is especially common in women after the menopause. Many people with osteoporosis have no symptoms and you may not even know that you have it. However, osteoporosis makes you more likely to have fractures (break bones), especially in your spine, hips and wrists.
HowOSSEORworks
OSSEOR, which contains the substance strontium ranelate, belongs to a group of medicines used to treat bone diseases.
OSSEOR works by reducing bone breakdown and stimulating rebuilding of bone and therefore reduces the risk of fracture. The newly formed bone is of normal quality.
if you are allergic to strontium ranelate or any of the other ingredients of OSSEOR (listed in section 6).
if you have or have had a blood clot (for example, in the blood vessels in your legs or lungs).
if you are immobilised permanently or for some time such as being wheel-chair bound, or confined to bed or if you are to undergo an operation or recovering from an operation. The
risk of vein thrombosis (blood clots in the leg or lungs) may be increased in the event of lengthy immobilisation.
if you have established ischaemic heart disease, or cerebrovascular disease, e.g. you have been diagnosed with a heart attack, stroke, or transient ischaemic attack (temporary reduction of blood flow to the brain; also known as “mini-stroke”), angina, or blockages of blood vessels to the heart or brain.
if you have or have had problems with your blood circulation (peripheral arterial disease) or if you have had surgery on the arteries of your legs.
if you have high blood pressure not controlled by treatment.
Talk to your doctor or pharmacist before taking OSSEOR:
if you are at risk of heart disease, this includes high blood pressure, high cholesterol, diabetes, smoking.
if you are at risk of blood clots.
if you have severe kidney disease.
Your doctor will evaluate the conditions of your heart and blood vessels regularly, generally every 6 to 12 months for as long you are taking OSSEOR.
During treatment, if you experience an allergic reaction (such as swelling of the face, tongue or throat, difficulty in breathing or swallowing, skin rash), you must immediately stop taking OSSEOR and seek medical advice (see section 4).
Potentially life-threatening skin rashes (Stevens-Johnson syndrome, toxic epidermal necrolysis and severe hypersensitivity reactions (DRESS)) have been reported with the use of OSSEOR.
Medicinal product no longer authorised
The highest risk of occurrence of serious skin reactions is within the first weeks of treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis and usually around 3-6 weeks for DRESS.
If you develop a rash or serious skin symptoms (see section 4), stop taking OSSEOR, seek urgent advice from a doctor and tell him that you are taking this medicine.
If you have developed Stevens-Johnson syndrome or toxic epidermal necrolysis or DRESS with the use of OSSEOR, you must not be re-started on OSSEOR at any time
If you are of Asian origin, you may be at higher risk of skin reactions.
The risk of these skin reactions in patients of Asian origin, particularly Han Chinese, may be predicted. Patients who have the HLA-A*33:03 and/or the HLA-B*58:01 genes are more likely to develop a serious skin reaction than those who do not have the genes.
Your doctor should be able to advise if a blood test is necessary before taking OSSEOR.
OSSEOR is not intended for use in children and adolescents (below the age of 18).
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
You should stop taking OSSEOR if you have to take oral tetracyclines such as doxycycline or quinolones such as ciprofloxacin (two types of antibiotics). You can take OSSEOR again when you have finished taking these antibiotics. If you are unsure about this ask your doctor or pharmacist.
If you are taking medicines containing calcium, you should leave at least 2 hours before you take OSSEOR.
If you take antacids (medicines to relieve heartburn) you should take them at least 2 hours after OSSEOR. If this is not possible, it is acceptable to take the two medicines at the same time.
If you need to have blood or urine tests to check your level of calcium, you should tell the laboratory that you are taking OSSEOR as it may interfere with some testing methods.
Food, milk and milk products reduce the absorption of strontium ranelate. It is recommended that you take OSSEOR in-between meals, preferably at bedtime at least two hours after food, milk or milk products or calcium supplements.
Do not take OSSEOR during pregnancy or when you are breastfeeding. If you take it by accident during pregnancy or breastfeeding, stop taking it straight away and talk to your doctor.
Osseor is unlikely to affect your ability to drive or use machines.
If you suffer from phenylketonuria (a rare, hereditary disorder of the metabolism) talk to your doctor before you start to take this medicine.
The treatment should only be started by a doctor with experience in treating osteoporosis. Always take this medicine exactly as your doctor or pharmacist has told you. Check with your
doctor or pharmacist if you are not sure.
OSSEOR is for oral use.
The recommended dose is one 2g sachet a day.
Medicinal product no longer authorised
It is recommended that you take OSSEOR at bedtime, preferably at least 2 hours after dinner. You may lie down immediately after taking OSSEOR if you wish.
Take the granules contained in the sachets as a suspension in a glass containing a minimum of 30 ml (approximately one third of a standard glass) of water. See instructions below. OSSEOR can interact with milk and milk products, so it is important that you mix OSSEOR only with water to be sure it works properly.
Empty the granules from the sachet into a glass; 
Add water;
Stir until the granules are evenly dispersed in the water.
Drink straight away. You should not leave more than 24 hours before you drink it. If for some reason you cannot drink the medicine straight away, make sure you stir it again before drinking.
Your doctor may advise you to take calcium and vitamin D supplements in addition to OSSEOR. Do not take calcium supplements at bedtime, at the same time as OSSEOR.
Your doctor will tell you how long you should continue to take OSSEOR. Osteoporosis-therapy is usually required for a long period. It is important that you continue taking OSSEOR for as long as your doctor prescribes the medicine.
If you take more sachets of OSSEOR than recommended by your doctor, tell your doctor or pharmacist. They may advise you to drink milk or take antacids to reduce the absorption of the active ingredient.
Do not take a double dose to make up for forgotten individual doses. Just carry on with the next dose at the normal time.
It is important that you continue taking OSSEOR for as long as your doctor prescribes the medicine. OSSEOR can treat your severe osteoporosis only if you continue to take it.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Common (may affect up to 1 in 10 people):
Medicinal product no longer authorised
Heart attack: sudden crushing pains in your chest which may reach your left arm, jaw, stomach, back and/or shoulders. Other symptoms may be nausea/vomiting, sweating, shortness of breath, palpitations, (extreme) tiredness and/or dizziness. Heart attack may occur commonly in patients at high risk for heart disease. Your doctor will not prescribe OSSEOR for you if you are at particular risk.
Blood clots in veins: pain, redness, swelling in your leg, sudden chest pain or difficulty breathing.
Rare (may affect up to 1 in 1000 people):
Signs of severe hypersensitivity reactions (DRESS): initially as flu-like symptoms and a rash on the face then an extended rash with a high temperature (uncommon), increased levels of liver enzymes seen in blood tests (uncommon) an increase in a type of white blood cell (eosinophilia) (rare) and enlarged lymph nodes (uncommon).
Very rare (may affect up to 1 in 10,000 people):
Signs of potentially life-threatening skin rashes (Stevens-Johnson syndrome, toxic epidermal necrolysis): initially as reddish target-like spots or circular patches often with central blisters on the trunk. Additional signs may include ulcers in the mouth, throat, nose, genitals and conjunctivitis (red and swollen eyes). These potentially life-threatening skin rashes are often accompanied by flu-like symptoms. The rash may progress to widespread blistering or peeling of the skin.
Very Common (may affect more than 1 in 10 people):
Itching, hives, skin rash, angioedema (such as swollen face, tongue or throat, difficulty in breathing or swallowing), bone, limb, muscle and/or joint pain, muscle cramps.
Common:
Vomiting, abdominal pain, reflux, indigestion, constipation, flatulence, difficulty in sleeping, inflammation of the liver (hepatitis), swelling in limbs, bronchial hyperreactivity (symptoms include
wheezing and shortness of breath and cough), increased level of a muscle enzyme (Creatine phosphokinase), increased levels of cholesterol.
Nausea, diarrhoea, headache, eczema, memory trouble, fainting fit, pins and needles, dizziness, vertigo. However, these effects were mild and short-lived and usually did not cause the patients to stop taking their treatment. Talk to your doctor if any effects become troublesome or persist.
Uncommon (may affect up to 1 in 100 people):
Seizures, oral irritation (such as mouth ulcers and gum inflammation), hair loss, feeling confused, feeling unwell, dry mouth, skin irritation.
Rare:
Reduction in production of blood cells in the bone marrow.
If you have stopped treatment due to hypersensitivity reactions, do not take OSSEOR again
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via thenationalreportingsystem listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Medicinal product no longer authorised
Do not use this medicine after the expiry date which is stated on the box and the sachet after EXP. The expiry date refers to the last day of that month.
This medicinal product does not require any special storage conditions.
Once reconstituted in water, the suspension is stable for 24 hours. However, it is recommended to drink the suspension immediately after preparation (see section 3).
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
The active substance is strontium ranelate. Each sachet contains 2 g of strontium ranelate.
The other ingredients are aspartame (E 951), maltodextrin, mannitol (E 421).
OSSEOR is available in sachets containing yellow granules for oral suspension.OSSEOR is supplied in boxes of 7, 14, 28, 56, 84 or 100 sachets.
Not all pack sizes may be marketed.
Les Laboratoires Servier 50, rue Carnot
92284 Suresnes cedex
France
Les Laboratoires Servier Industrie 905, route de Saran
45520 Gidy France
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.
S.A. Servier Benelux N.V. Tel: +32 (0)2 529 43 11
Сервие Медикал ЕООД Тел.: +359 2 921 57 00
UAB "SERVIER PHARMA" Tel: +370 (5) 2 63 86 28
S.A. Servier Benelux N.V. Tel: +32 (0)2 529 43 11
Servier s.r.o.
Tel: +420 222 118 111
Servier Danmark A/S Tlf: +45 36 44 22 60
Galepharma Ltd
Tel: +(356) 21 247 082
Medicinal product no longer authorised
Servier Deutschland GmbH Tel: +49 (0)89 57095 01
Servier Nederland Farma B.V. Tel: +31 (0)71 5246700
Servier Laboratories OÜ Tel:+ 372 664 5040
Servier Danmark A/S Tlf: +45 36 44 22 60
ΣΕΡΒΙΕ ΕΛΛΑΣ ΦΑΡΜΑΚΕΥΤΙΚΗ ΕΠΕ Τηλ: +30 210 939 1000
Servier Austria GmbH Tel: +43 (1) 524 39 99
Laboratorios Farmacéuticos Rovi, S.A. Tel: +34 91 375 62 30
Servier Polska Sp. z o.o. Tel: +48 (0) 22 594 90 00
Les Laboratoires Servier Tel: +33 (0)1 55 72 60 00
Servier Portugal, Lda Tel.: +351 21 312 20 00
Servier Pharma, d. o. o. Tel.: +385 (0)1 3016 222
Servier Pharma SRL Tel: +40 21 528 52 80
Servier Laboratories (Ireland) Ltd. Tel: +353 (0)1 6638110
Servier Pharma d.o.o. Tel.: +386 (0)1 563 48 11
Servier Laboratories c/o Icepharma hf Sími: +354 540 8000
Servier Slovensko spol. s r.o. Tel.:+421 (0) 2 5920 41 11
I.F.B. Stroder S.r.l. Tel: +39 06 669081
Servier Finland Oy
P./Tel: +358 (0)9 279 80 80
C.A. Papaellinas Ltd.Τηλ: +357 22741741
Servier Sverige AB
Tel: +46 (0)8 522 508 00
SIA Servier Latvia Tel. +371 67502039
Servier Laboratories Ltd Tel: +44 (0)1753 666409
Medicinal product no longer authorised
Medicinal product no longer authorised
Taking into account the PRAC Assessment Report for the non-interventional imposed PASS final study report for the medicinal product mentioned above, the scientific conclusions of CHMP are as follows:
The PASS final study report submitted by the MAH complies with their obligation to perform a PASS to evaluate risk of serious cardiac disorders as imposed during the Article 20 procedure EMA/112925/2014.
Therefore, in view of available data regarding the PASS final study report, the PRAC considered that changes to the conditions of the marketing authorization were warranted.
The CHMP agrees with the scientific conclusions made by the PRAC.
On the basis of the scientific conclusions for the results of the study for the medicinal product mentioned above, the CHMP is of the opinion that the benefit-risk balance of this medicinal product is unchanged, subject to the proposed changes to the product information.
Medicinal product no longer authorised
The CHMP is of the opinion that the terms of the marketing authorisation of the medicinal product mentioned above should be varied.